Blood · 2005 · 54 citations · 20 references
MedicineCancer BiologyOncologyMolecular OncologyNeoplasiaOncogenesCancer EtiologyLymphoid NeoplasmsLymphoid TumorsOncogenic VirusesEpstein-barr Virus - Associated Lymphoid NeoplasmsEpstein-barr Virus LatencyEpstein-barr Virus OncogenesisLymphoma Pathogenesis
The antiviral compound azidothymidine (AZT), alone or in combination with other agents, induces apoptosis in early-passage, Epstein-Barr virus-positive Burkitt lymphoma (EBV+ BL) lines and has clinical activity in EBV+ BL. We report here a mechanism of AZT's antitumor activity. The nuclei of these cells contain activated nuclear factor-kappaB (NF-kappaB) subunits p50, c-Rel, RelB, and p52, but not p65. Treatment of primary EBV+ BL lines with AZT inhibited NF-kappaB within 1 to 2 hours. This was followed by up-regulation of EBV gene expression including viral thymidine kinase (vTK) and apoptosis. Subclones of EBV+ BL cells that demonstrated activated p65 were resistant to AZT. In EBV+ BLs, AZT but not ganciclovir (GCV) was highly phosphorylated to its monophosphate form (AZT-MP). Phosphorylation, as well as apoptosis, was markedly enhanced in the presence of hydroxyurea. AZT inhibits NF-kappaB and up-regulates EBV gene expression in primary EBV+ BLs. AZT with hydroxyurea may represent an inexpensive, targeted regimen for endemic BL.
20
Kenneth M. Izumi, Elliott Kieff · Proceedings of the National Academy of Sciences · 1997 · 398 citations · Full text
Ellen Cahir-McFarland, Kara Carter, Andreas Rosenwald et al. · Journal of Virology · 2004 · 233 citations · Full text